DDInter1568 DDInter1376
Ranitidine is a commonly used drug, classified as a histamine H2-receptor antagonist, and belongs to the same drug class as [cimetidine] and [famotidine]. This drug helps to prevent and treat gastric-acid associated conditions, including ulcers, because of its ability to decrease gastric acid secretion.[A176759,L10818] Ranitidine is often referred to as Zantac, and is available in various forms, including tablet, injection, and effervescent tablet preparations.[L10818,F4253] The prevalence of GERD is thought to be 10-20% in western countries. Ranitidine has proven to be an effective treatment for relieving uncomfortable symptoms of gastric acid associated conditions and is therefore widely used in GERD and other gastric-acid related conditions.[A176849,L10818]
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Ranitidine {u} (Compound) resembles {v} (Compound) Nizatidine
Ranitidine {u} (Compound) binds {v} (Gene) CYP3A4
Ranitidine {u} (Compound) upregulates {v} (Gene) GPATCH8
Ranitidine {u} (Compound) is included by {v} (Pharmacologic Class) Histamine H2 Receptor Antagonists
Ranitidine {u} (Compound) downregulates {v} (Gene) SDC1
Ranitidine {u} (Compound) causes {v} (Side Effect) Weight decreased
Ranitidine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Etodolac
Ranitidine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tubocurarine
Ranitidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nilotinib
Ranitidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Theophylline
Ranitidine (Compound) resembles Nizatidine (Compound)
Ranitidine (Compound) binds CYP3A4 (Gene)
Ranitidine (Compound) upregulates GPATCH8 (Gene)
Ranitidine (Compound) is included by Histamine H2 Receptor Antagonists (Pharmacologic Class)
Ranitidine (Compound) downregulates SDC1 (Gene)
Ranitidine (Compound) causes Weight decreased (Side Effect)
Ranitidine may cause a minor interaction that can limit clinical effects when taken with Etodolac
Ranitidine may cause a minor interaction that can limit clinical effects when taken with Tubocurarine
Ranitidine may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Ranitidine may cause a moderate interaction that could exacerbate diseases when taken with Theophylline